Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Parulekar, W
  • Chapman, JW
  • Aparicio, S
  • Murray, Y
  • Boyle, FM
  • Di Leo, A
  • Kaufman, B
  • Levy, C
  • Manikhas, A
  • Martin, M
  • Pritchard, KI
  • Schwartzberg, LS
  • Burnell, MJ
  • Dent, S
  • Ellard, S
  • Tonkin, KS
  • Whelan, Timothy
  • Lemieux, J
  • Bordeleau, Louise
  • Gelmon, KA

publication date

  • May 20, 2011